Study details
Enrolling now
Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS
Vanderbilt University Medical Center
NCT IDNCT07189936ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
50
Study length
about 3.5 years
Ages
18+
Locations
1 site in TN
About this study
This trial is testing whether a treatment called 2-HOBA can help with immune markers and orthostatic tachycardia in people with Long COVID and POTS. The trial compares 2-HOBA to a placebo (an inactive substance) over 28 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take To Measure levels of circulating monocyte/ T cell doublets at Baseline
- 2.Take To measure levels of circulating monocyte/ T cell doublets after 28 days of 2 HOBA treatment
- 3.Take To measure levels of circulating monocyte/ T cell doublets after 28 days of Placebo treatment
- +3 more
PhasePhase 2
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low15%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Body systems
Infectious